SUBSCRIBE
SUBSCRIBE

Phase III

Policy
Biopharma Update on the Novel Coronavirus: September 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
September 22, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: September 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
September 22, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 25
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
September 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: September 23
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
September 22, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
Tagrisso demonstrated an 82% reduction in the risk of central nervous system recurrence or death. The safety and tolerability of the product in the Phase III trial was consistent with previous trials in the metastatic EGFRm NSCLC setting.
September 22, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
ESMO: Genentech Shares Data from Phase III Triple-Negative Breast Cancer Trials
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
September 21, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
September 21, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
ESMO News: AstraZeneca, Merck, Janssen, Amgen and More
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
September 21, 2020
 · 
4 min read
 · 
Mark Terry
Drug Development
ESMO: Lynparza Provides 31% Survival Improvement in Prostate Cancer Indications
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
September 21, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
September 18, 2020
 · 
4 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Press Releases
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
January 21, 2026
 · 
7 min read
Press Releases
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026
 · 
5 min read
Press Releases
Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
January 21, 2026
 · 
5 min read
Press Releases
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026
 · 
5 min read
Press Releases
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
 · 
7 min read
Press Releases
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
13 min read
Press Releases
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 19, 2026
 · 
13 min read
Press Releases
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
9 min read
Press Releases
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
January 19, 2026
 · 
17 min read
Press Releases
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 16, 2026
 · 
6 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
 · 
7 min read
Press Releases
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
January 15, 2026
 · 
34 min read
Press Releases
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant®
January 15, 2026
 · 
5 min read
Press Releases
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 14, 2026
 · 
13 min read
Press Releases
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 14, 2026
 · 
9 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Press Releases
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
January 13, 2026
 · 
19 min read
Press Releases
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
January 13, 2026
 · 
9 min read
Load More